Liver Diseases  >>  TMC647055  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TMC647055 / J&J
NCT01724086 / 2012-002555-42: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus

Checkmark Olysio + GSK-805 + TMC-055 combination in chronic genotype 1 hep C infected patients
Mar 2015 - Mar 2015: Olysio + GSK-805 + TMC-055 combination in chronic genotype 1 hep C infected patients
Completed
2a
90
Europe
TMC647055, JNJ-42039556-AMR-G-001, TMC435, Ritonavir, Ribavirin, Pegylated interferon alpha-2a (PegIFN), GSK2336805
Janssen R&D Ireland
Chronic Hepatitis C
09/14
12/14
NCT01852604: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

Checkmark EASL 2014: HELIX-1
Mar 2014 - Mar 2014: EASL 2014: HELIX-1
Checkmark EASL 2014: HELIX-1
Mar 2014 - Mar 2014: EASL 2014: HELIX-1
Checkmark HELIX-1 trial for hep C infection
More
Completed
2
143
US
Samatasvir, Simeprevir, Ribavirin (RBV), TMC647055, Ritonavir (RTV), Pegylated interferon (Peg-IFN), Samatasvir matching placebo
Merck Sharp & Dohme LLC, Janssen Research & Development, LLC
Chronic Hepatitis C Virus
04/15
04/15

Download Options